Table 3. Univariate analysis of (a) progession-free survival and (b) overall survival.

	n	Hazard ratio (95% CI)	P-value
(a)
Gender
Female	12	1	0.7
Male	35	1.15 (0.5–2.29)	—
Age
Per year	47	1 (0.99–1.02)	0.75
Line of therapy
First	21	1	0.35
Second+	26	0.75 (0.4–1.38)	—
Stage
Local disease	11	1	0.03
Nodal±distant mets	36	2.52 (1.09–5.77)
PS
1	18	1	0.13
2 or above	29	1.6 (0.86–2.97)	—
(b)
Gender
Female	12	1	0.81
Male	35	1.1 (0.49–2.45)	—
Age
Per year	47	1.01 (0.99–1.03)	0.41
Line
First	21	1	0.06
Second+	26	0.51 (0.25–1.02)	—
Stage	11	1	0.27
Local disease	36	1.61 (0.69–3.73)	—
Nodal±distant mets
PS
1	18	1	0.1
2 or above	29	1.84 (0.89–3.82)	—